BCL2L11 and myelodysplastic syndrome: The reduced expression of pro-apoptotic BIM in higher-risk MDS supported the notion that an acquired resistance to apoptosis occurred upon disease progression, which is in line with our cell culture-based data on ABT-199-induced apoptosis induction [7].